STANDARD BIOTOOLS INC
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Unregistered Sales of Equity Securities and Use of Proceeds
None.
Issuer Purchases of Equity Securities
On February 6, 2024, our board of directors authorized a share repurchase program (the “2024 Share Repurchase Program”) pursuant to which we may repurchase up to $50.0 million of shares of our common stock in the open market, in one or more Rule 10b5-1 trading plans, or in negotiated transactions through March 1, 2026. The repurchases are contingent upon favorable market and business conditions and are funded by cash on hand. The program does not obligate us to acquire any specific number of shares. As of March 31, 2024, we have repurchased 4,119,486 shares of our common stock under the 2024 Share Repurchase Program.
The following table provides monthly information with respect to the shares of common stock repurchased by us during the three months ended March 31, 2024:
| Period | Total Number of Shares Purchased | Average Price Paid Per Share (1) | Total Number of Shares Purchased as Part of Publicly Announced Program | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program |
|---|---|---|---|---|
| January 1-31, 2024 | — | $— | — | $50.0 million |
| February 1-28, 2024 | — | $— | — | $50.0 million |
| March 1-31, 2024 | 4,119,486 | $2.68 | 4,119,486 | $39.0 million |
1 Average price paid per share includes commission fees.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.